Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Smaller Airways Increase COPD Risk for Women

Structural differences in lung airways between men and woman may be the cause of differences in chronic obstructive pulmonary disease (COPD) prevalence and outcomes between the sexes. According to a large, multicenter study published in the journal Radiology, researchers found that even among adults who have never smoked, or who have smoked less than 100 cigarettes in their lifetime, lung airways were smaller in women, which can lead to a higher risk for lung disease.

COPD refers to a group of diseases, such as emphysema and chronic bronchitis, that cause airflow blockage and breathing-related problems. More than 15 million Americans have COPD, according to the Centers for Disease Control and Prevention.

Overall, men have a higher rate of diagnosis and mortality, but with changes in smoking behavior and increasing urbanization, the prevalence of COPD in women is on the rise.

“The prevalence of COPD in women is fast approaching that seen in men, and airway disease may underlie some of the high COPD numbers in women that we are seeing,” said the study’s lead author, Surya P. Bhatt, M.D., M.S.P.H., associate professor of medicine, Division of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham. “When airways narrow due to cigarette smoking, the impact on symptoms and survival is greater in women than in men.”

The assumption that women have smaller airways is based on comparisons of the trachea and main stem bronchi, but few studies have compared distal airways in normal individuals or accounted for differences in lung size.

For this study, researchers analyzed data from nearly 10,000 participants enrolled in Genetic Epidemiology of COPD (COPDGene), a prospective multicenter observational cohort study of current and former smokers, as well as never smokers, between the ages of 45 and 80 years, at 21 clinical centers across the United States. The researchers looked at data of never, current and former smokers enrolled in COPDGene from January 2008 to June 2011 and followed up longitudinally until November 2020.

Airway disease on CT was quantified using seven metrics: airway wall thickness, wall area percent, Pi10 (square root of the wall thickness of a hypothetical airway with internal perimeter of 10 mm) for airway wall, lumen (airway passage in which air flows through) diameter, airway volume, total airway count and airway fractal dimension for airway lumen.

Each airway metric was calculated and adjusted for age, height, race, body mass index, pack-years of smoking, current smoking status and total lung capacity.

“The growth of airways and lungs in early life is generally more proportionate in women than in men,” Dr. Bhatt said.

In 420 never-smokers, CT scans revealed that men had thicker airway walls than women, whereas, after accounting for height and total lung capacity, airway lumen dimensions were lower in women than in men.

In 9,363 current and former smokers, men had greater wall thickness, whereas women had narrower segmental lumen diameter. A unit change in each of the airway metrics (higher wall or lower lumen measure) resulted in lower lung function, more dyspnea (shortness of breath), poorer respiratory-quality of life, lower six-minute walk distance and worse survival in women compared with men.

“The differences in airway dimensions even after adjusting for height and lung size, and the greater impact of changes in airway size on clinical outcomes in women, was remarkable in that women appear to have a lower reserve against developing airway disease and COPD,” Dr. Bhatt noted.

Dr. Bhatt noted that the research implicates that sex differences should be factored into the development of new therapies for airway disease.

About RSNA.

 

SourceRSNA
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy